https://www.selleckchem.com/pr....oducts/rocaglamide.h
Assessing reversibility of pulmonary vascular changes through vasoreactivity testing (VRT) optimizes end-stage heart failure patient selection for heart transplant. All efforts should be made to unload the left ventricle and reduce pulmonary vascular resistance to effectively exclude irreversible pulmonary hypertension. We reviewed our centre's cardiac transplant registry database (2009-2017) for VRT and compared haemodynamic responses with 40ppm inhaled NO (n=14), 14-17μg inhaled iloprost (n=7), and 24h 0.1μg/kg/min intravenous lev
Like
Comment
Share
